Name: Melissa Vos

Position/Title: Research Group Leader, PhD, at the Institute of Neurogenetics

Address: Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

Phone: +49-451-3101 8203

2003 – 2007: Biomedical sciences (Masters in Biomedical Science); KU Leuven, Belgium graduated with Distinction, Advisor: Dr. Marc Van Ranst (Characterization of novel Papillomaviruses)

2009 – 2012: Ph.D. in Biomedical sciences; KU Leuven, Center for Human Genetics, VIB Center for the Biology of Disease, Leuven, Belgium, Advisor: Patrik Verstreken

2017- current: Group leader ‘Drosophila models of neurodegeneration’ at the Institute of Neurogenetics

06/2012: Author of the month; Award from the Center for Human genetics KU Leuven, Belgium                                     

2013:  Runner-up in the Larry Sandler award for best dissertation in the Drosophila field, GSA

09/2014:  Prize of the Research Council (7500€) to stimulare young postdoctoral researchers, KU Leuven, Belgium

09/2014: Special acknowledgement baron Simonart foundation to encourage research in clinical pharmacology, Belgium


2009-2012: Predoctoral Fellowship; IWT Vlaanderen, Belgium; Fellowship obtained after personal defense of the project

2013: Postdoctoral Fellowship; KU Leuven, Belgium

2014-2016: Post-doctoral fellowship; FWO, Belgium

10/2013: Travel grant (400€); GEO-PD meeting, Lubeck, Germany

12/2013:  Travel grant; FWO, mitochondrial Keystone meeting, Santa Fe, USA

2014: Junior Mobility award for a stay abroad, KU Leuven, Belgium

2014: Award for a long stay abroad, FWO, Belgium

2015: Postdoctoral felloyship; EMBO



The Implication of Lipids in Parkinson’s Disease Pathogenesis
Principal Investigator: Melissa Vos
Funding Agency: University of Lübeck, Germany (Intramural funding)
Funding Period: 01.01.2016-31.12.2017
Amount: € 75,000

Elucidating the Interaction between Mitochondria and Lipids in Parkinson’s Disease
Principal Investigator: Melissa Vos
Funding Agency: Else-Kröner-Fresenius Stiftung
Funding Period: 01.09.2017-31.08.2020
Amount: € 294,030


Advanced Biology of the Cell/Neuron

Drosophila as animal model in the study of neurodegeneration

Invited Talks

  1. Vos M. Vitamin K2 is a mitochondrial electron carrier that rescues Pink1 deficiency. GEO-PD meeting, Lübeck, Germany, October 2013.
  2. Vos M. Vitamin K2 as a potential novel therapeutic strategy in Parkinson’s disease. Ophtalmology Conference, OMICS, Baltimore, USA, June 2014.
  3. Vos M. Mitochondrial dysfunction in Parkinson’s disease and role of vitamin K2. Neurology seminar series, Université Catholique de Louvain, Brussels, Belgium, January 2015
  1. Dulovic-Mahlow M, Trinh J, Kandaswamy KK, Braathen GJ, Di Donato N, Rahikkala E, Beblo S, Werber M, Krajka V, Busk ØL, Baumann H, Al-Sannaa NA, Hinrichs F, Affan R, Navot N, Al Balwi MA, Oprea G, Holla ØL, Weiss MER, Jamra RA, Kahlert AK, Kishore S, Tveten K, Vos M, Rolfs A, Lohmann K. De Novo Variants in TAOK1 Cause Neurodevelopmental Disorders. Am J Hum Genet 2019;1:213-220.
  2. Vos M, Geens A, Böhm C, Deaulmerie L, Swerts J, Rossi M, Craessaerts K, Leites EP, Seibler P, Rakovic A, Lohnau T, De Strooper B, Fendt SM, Morais VA, Klein C, Verstreken P. Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency. J Cell Biol 2017;3:695-708.
  3. Vos M, Verstreken P, Klein C. Stimulation of electron transport as potential novel therapy in Parkinson’s disease with mitochondrial dysfunction. Biochem Soc Trans 2015;2:275-279.